212. Ippolito D., Tersigni C., Scambia G., Simone N.D. Adipokines, an adipose tissue and placental product with biological functions during pregnancy // Biofactors. 2012. Vol. 38, № 1. P. 14–23.
213. Prieto D.M., Markert U.R. MicroRNAs in pregnancy // J. Reprod. Imm. 2011. Vol. 88, № 2. P. 106–111.
214. Catalano P.M., Hoegh M., Minium J. et al. Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism // Diabetologia. 2006. Vol. 49, № 7. P. 1677–1685.
215. Nien J.K., Mazaki-Tovi S., Romero R. et al. Adiponectin in severe preeclampsia // J. Perinat Med. 2007. Vol. 35, № 6. P. 503–512.
216. Nakatsukasa H., Masuyama H., Takamoto N., Hiramatsu Y. Circulating leptin and angiogenic factors in preeclampsia patients // Endocr J. 2008. Vol. 55, № 3. P. 565–557.
217. Fasshauer M., Waldeyer T., Seeger J. et al. Serum levels of the adipokine visfatin are increased in pre-eclampsia // Clin Endocrinol. 2008. Vol. 69, № 1. P. 69–73.
218. Vanhoutte P.M. Endothelial dysfunction: the first step toward coronary arteriosclerosis // Circul. J. 2009. Vol. 73, № 4. P. 595–601.
219. Xie H., Tang S-Y., Luo X-H. et al. Insulin-like effects of visfatin on human osteoblasts // Calcif. Tissue Int. 2007. Vol. 80, № 3. P. 201–210.
220. Fasshauer M., Waldeyer T., Seeger J. et al. Serum levels of the adipokine visfatin are increased in pre-eclampsia // Clin Endocrinol (Oxf). 2008. Vol. 69, № 1. P. 69–73.
221. Adali E., Yildizhan R., Kolusari A. et al. Increasedvisfatin and leptin in pregnancies complicated by preeclampsia // J. Maternal Fetal Neonatal Med. 2009. Vol. 22, № 10. P. 873–879.
222. Hu W. Serum visfatin levels in late pregnancy and pre-eclampsia // Acta Obstet. Gynecol. Scand. 2008. Vol. 87. P. 413–418.
223. Сидорова И.С., Макаров И.О., Солоницын А.Н. и др. Характер изменений маркеров ангиогенеза при гестозе // Акушерство и гинекология. 2009. № 3. С. 38–41.
224. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018. Vol. 39, № 33. P. 3021–3104.
225. Дубровина С.О., Муцалханова Ю.С., Васильева В.В. Ранние предикторы преэклампсии // Акушерство и гинекология Санкт-Петербурга. 2018. № 1. С. 26–30.
226. Дубровина С.О., Муцалханова Ю.С., Васильева В.В. Анализ эффективности миникомбинированного теста для прогноза поздней преэклампсии средней тяжести // Фарматека. 2018. № 6. С. 23–28.
227. Dubrovnik S., Gimbut V., Mutsalkhanova U. Evalutaion of early markers of preeclampsia // Preeclampsia. Risk factors, pathogenesis and potential treatment. 2020. Published by Nova Science Publishers, New York.
228. Timofeeva A.V., Gusar V.A., Kan N.E. et al. Identification of potential early biomarkers of preeclampsia // Placenta. 2018. Vol. 61. P. 61–71.
229. Iacobelli S., Bonsante F., Robillard P-Y. Comparison of risk factors and perinatal outcomes in early onset and late onset preeclampsia: A cohort based study in Reunion Island // J Reprod Immunol. 2017. Vol. 123. P. 12–16.
230. Jardim L.L., Alves Rios D.R., Perucci L.O. et al. Is the imbalance between pro-angiogenic and anti-angiogenic factors associated with preeclampsia? // Clin Chim Acta. 2015. Vol. 447. P. 34–38.
231. Panaitescu A.M., Syngelaki A., Prodan N. et al. Chronic hypertension and adverse pregnancy outcome: a cohort study // Ultrasound Obstet Gynecol. 2017. Vol. 50, № 2. P. 228–235.
232. Henderson J.T., Whitlock E.P., O’Connor E. et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force // Ann Intern Med. 2014. Vol. 160, № 10. P. 695–703.
233. Keikkala E., Vuorela P., Laivuori H. et al. First trimester hyperglycosylated human chorionic gonadotrophin in serum-a marker of early-onset preeclampsiа // Placenta. 2013. Vol. 34, № 11. P. 1059–1065.
234. Tayyar A., Krithinakis K., Wright A. Mean arterial pressure at 12, 22, 32 and 36 weeks’ gestation in screening for pre-eclampsia // Ultrasound Obstet Gynecol. 2016. Vol. 47, № 5. P. 573–579.
235. Wang C., Wang X.Y., Yang H.X. Effect of maternal age on pregnancy outcomes in Beijing // Zhonghua Fu Chan Ke Za Zhi. 2017. Vol. 52, № 8. P. 514–520.
236. Ali S.M., Khalil R.A. Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy // Expert Opin Ther Targets. 2015. Vol. 19, № 11. P. 1495–1515.
237. Matwejew E., Cowans N.J., Stamatopoulou A., Spencer K. Maternal serum ADAM-12 as a potential marker for different adverse pregnancy outcomes // Fetal diagnosis and therapy. 2010. Vol. 27, № 1. P. 32–39.
238. Mendola P., Ghassabian A., Mills J.L. et al. Retinol-binding protein 4 and lipids prospectively measured during early to mid-pregnancy in relation to preeclampsia and preterm birth risk // Am J Hypertens. 2017. Vol. 30, № 6. P. 569–576.